Evidence supporting the use of: Astragaloside IV
For the health condition: Fibrosis

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Astragaloside IV, a saponin and active component derived from Astragalus membranaceus, has been investigated in a number of preclinical studies for its potential anti-fibrotic effects. Research over the past decade has largely focused on animal models and in vitro experiments. Studies have demonstrated that Astragaloside IV can attenuate fibrosis in organs such as the liver, heart, lungs, and kidneys. The proposed mechanisms include inhibition of the TGF-β/Smad signaling pathway, reduction of oxidative stress, suppression of inflammatory cytokines, and prevention of epithelial-mesenchymal transition (EMT), all of which are key contributors to fibrotic progression (PMID: 32197408, PMID: 29522934).

Despite promising preclinical findings, robust clinical evidence in humans is lacking. No large-scale randomized controlled trials have been published to confirm its efficacy or safety for treating fibrosis in patients. As such, while there is a growing body of scientific literature supporting its potential, the evidence is not yet sufficient for strong clinical recommendations. The current evidence level is therefore moderate (rated 3/5), largely on the basis of animal and cell culture studies rather than human trials. Astragaloside IV is not known to be a part of traditional anti-fibrosis treatments, but its use is justified by emerging scientific research rather than historical precedent.

More about Astragaloside IV
More about Fibrosis

Products containing Astragaloside IV

We currently have no products on Vitabase that contain this ingredient.